Endocrine Insider
October 29, 2008 

This month's mailing of Endocrine News included the Society's latest clinical practice guideline, Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism.  The guideline was developed by a task force of content experts chaired by John W. Funder, M.D., Ph.D. The guideline was approved by The Endocrine Society's Council in January 2008 and published in the September issue of the Journal of Clinical Endocrinology and Metabolism. Some of the issues addressed in the guideline are the definition and clinical significance of primary aldosteronism, subtype classification, and treatment.

The Society's next guideline, Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk, will be mailed with the November issue of Endocrine News. Developed by a task force led by James L. Rosenzweig, M.D., the guideline examines the definition and diagnosis of metabolic syndrome, the absolute risk assessment, and the treatments to prevent atherosclerotic cardiovascular disease and type 2 diabetes.

All published Society clinical practice guidelines are available at http://www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm. The guideline on metabolic syndrome will be available in mid-November.

The Society has nine other guidelines nearing completion and coming soon. Please contact the Society's Government & Public Affairs department at govt-prof@endo-society.org for more information.